Second Chance for Moms Act

HR 7823, the Second Chance for Moms Act, requires new labeling on mifepristone (a medication used in medical abortions) and establishes a hotline. The bill mandates that mifepristone packaging include a warning label stating that natural progesterone may counteract the drug's effects, based on a statement from the American Society for Reproductive Medicine. It also directs the creation of a 24/7 toll-free hotline to provide support for women seeking to reverse the drug's effects. This bill directly affects pharmaceutical manufacturers (through labeling changes), healthcare providers, and women using mifepristone, with the labeling requirement taking effect six months after enactment.